CTi Biopharma

CTIC NASDAQ
0.8678
+0.0677
+8.46%
已收盘, 16:10 05/20 EDT
开盘
0.8163
昨收
0.8001
最高
0.9150
最低
0.8005
成交量
55.04万
成交均量(3M)
27.38万
52周最高
5.36
52周最低
0.6001
换手率
0.95%
市值
5,031.39万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供CTi Biopharma CTIC股票价格,CTi Biopharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
展开 >

最近浏览

名称
价格
涨跌幅